In people taking levothyroxine for hypothyroidism, about half have low levels of free triiodothyronine in their blood even when their thyroid-stimulating hormone levels are within the normal range.
Mechanism
Synthesis from 1 study
People with hypothyroidism who take levothyroxine often still have low levels of the active thyroid hormone fT3, even when their TSH looks normal, because their bodies don’t consistently convert the medication into fT3 in muscles and fat — a process that varies from person to person and isn’t...
Most probable mechanism
When people with hypothyroidism take levothyroxine (L-T4), their bodies are supposed to turn it into the active hormone fT3 in tissues like muscle and fat, but in many people, this conversion doesn’t happen enough — even when their TSH looks normal — leading to low fT3 levels that affect energy use and movement, as shown in studies like 10.1210/jc.2017-00224.
Exogenous levothyroxine (L-T4) is administered orally and absorbed into circulation, providing the sole source of thyroid hormone in treated hypothyroid patients, as measured across a range of doses in individuals with normal TSH levels (10.1210/jc.2017-00224).
Peripheral tissues, including skeletal muscle and adipose tissue, convert L-T4 to free triiodothyronine (fT3) via type 2 deiodinase (D2) enzymes, but this conversion varies significantly between individuals despite similar L-T4 dosing and normal TSH levels (10.1210/jc.2017-00224).
Variability in D2 activity leads to suboptimal serum fT3 levels in a substantial subset of patients, as evidenced by the direct correlation between fT3 and metabolic outcomes like resting energy expenditure and carbohydrate oxidation, which are independent of TSH and fT4 levels (10.1210/jc.2017-00224).
Low fT3 levels persist despite normal TSH because TSH primarily reflects pituitary sensing of fT4, not tissue-level fT3 availability, allowing a disconnect between central thyroid feedback and peripheral hormone action (10.1210/jc.2017-00224).
Less supported by current evidence, but not ruled out
In some individuals, higher body fat may increase signals like insulin and bile acids that boost the conversion of L-T4 to fT3 in fat and muscle, but this mechanism may not work consistently — leading to unpredictable fT3 levels even with the same L-T4 dose (10.1210/jc.2017-00224).
Increased adiposity elevates insulin secretion and expands the bile acid pool, which in animal models stimulate type 2 deiodinase (D2) expression in muscle and adipose tissue (10.1210/jc.2017-00224).
In L-T4-treated humans, higher BMI and fat mass correlate with higher fT3 levels, suggesting adipose tissue may act as a variable amplifier of peripheral T3 production (10.1210/jc.2017-00224).
This pathway may explain why some patients maintain normal fT3 despite low conversion efficiency, while others with similar L-T4 doses and TSH levels develop low fT3 — but it does not account for all cases, particularly in lean individuals (10.1210/jc.2017-00224).
Evidence from Studies
Supporting (1)
Community contributions welcome
Thyroid Function Variation in the Normal Range, Energy Expenditure, and Body Composition in L-T4–Treated Subjects
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.